• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

UCB S.A. (Euronext: UCB)

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). *

 

	Start	1928-01-01 established
	Group	UCB (Group)
	Industry	pharmaceutical
	Industry 2	CNS drug
	Person	Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
	Region	Brussels
	Country	Belgium
	Street	60 Allée de la Recherche
	City	1070 Brussels
	Tel	+32-2-559-9999
		Address record changed: 2018-07-24
Basic data	Employees	G: 5,001 to 10,000 (2017-12-31)
	Currency	EUR
	Annual sales	4,632,000,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	823,000,000 (2018-12-31)
	Cash	1,049,000,000 (2017-12-31)
		* Document for �About Section�: Activiomics Ltd.. (12/6/10). "Press Release: Activiomics Signs Technology Agreement with UCB".
		Record changed: 2019-04-19

Advertisement

More documents for UCB (Group)

• [1] Rinri Therapeutics Ltd.. (5/20/19). "Press Release: Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss". Sheffield....
• [2] UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels....
• [3] UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels....
• [4] UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels....
• [5] UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough....
• [6] UCB S.A.. (2/11/19). "Press Release: UCB and Epilepsy Society Announce Pioneering UK Genomics R&D collaboration". Slough & Brussels....
• [7] UCB S.A.. (7/13/18). "Press Release: UCB and Amgen Resubmit Biologics Licence Application (BLA) for Evenity (Romosozumab) to the U.S. FDA". Brussels & Thousand Oaks, CA....
• [8] StrideBio, Inc.. (6/13/18). "Press Release: StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform". Durham, NC....
• [9] Science 37 Inc.. (5/3/18). "Press Release: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home". Playa Vista, CA....
• [10] UCB S.A.. (4/27/18). "Press Release: UCB Announces Positive CHMP Opinion for Cimzia (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis". Brussels....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.